X

Drug Profile

Bimoclomol

Alternative Names: ABT 822; BRLP 42

Latest Information Update: 23 May 2011

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biorex
Class Anti-ischaemics; Antihyperglycaemics; Small molecules
Mechanism of Action Protein synthesis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Diabetic complications; Diabetic neuropathies; Ischaemic heart disorders

Most Recent Events

17 May 2011 Orphazyme acquires bimoclomol from CytRx Corporation
12 Oct 2004 CytRx Corporation has acquired all the clinical, pharmacological and intellectual property assets of Biorex
04 Dec 2001 Abbott Laboratories returned all rights to bimoclomol to Biorex

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com